Amyotrophic Lateral Sclerosis Treatment Market PPT: Trends and Dynamics, Drivers, Competitive landscape and Future Opportunities 2032
                     Global Amyotrophic 
Lateral Sclerosis Treatment 
Market Research and 
Forecast Report 2024-2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved 
About IMARC Group
In ternat ional  Market  Analys is  Research and Consul t ing Group is  a leading adv iser  on management  
s t rategy and market  research wor ldwide.  We par tner  wi th c l ients  in  a l l  regions and indust ry  
vert ica ls  to  ident i fy  thei r  h ighest -value oppor tuni t ies,  address thei r  most  cr i t ica l  chal lenges,  and 
t ransform thei r  bus inesses.
IMARC’s in format ion products  inc lude major market ,  sc ient i f ic ,  economic and technological  
developments  for  bus iness leaders  in  pharmaceut ica l ,  indust r ia l ,  and h igh technology 
organizat ions.  Market  forecasts  and indust ry  analys is  for  b iotechnology,  advanced mater ia ls ,  
chemicals ,  food and beverage,  t ravel  and tour ism, nanotechnology and novel  process ing methods 
are at  the top of  the company’s  exper t ise.
IMARC’s ta i lored approach combines unfathomable ins ight  in to the dynamics o f  companies and 
markets wi th c lose cooperat ion at  a l l  levels  of  the c l ient  organizat ion.  This ensures that  our  c l ients 
achieve unmatchable compet i t ive advantage,  bui ld  more pro f ic ient  organizat ions,  and secure 
las t ing resul ts .
Accord ing  t o  t he  la tes t  r epor t  by  IMARC Group,  t i t l ed  " Amyotroph i c  La tera l  
Sc l eros is  T reatment  Market :  G l oba l  Indust ry  T rends ,  Share ,  S ize ,  Growth ,  
Oppor tun i ty  and  Forecast  2024-2032 ,"  t he  g loba l  amyo t roph i c  la t e ra l  sc le ros i s  
t r ea tment  marke t  s i ze  reached US$  754. 4  M i l l i on  in  2023 .
Report Amyot roph ic  la t e ra l  sc le ros is  (ALC) ,  a l so  known as  Lou  Gehr i g ' s  d isease,  i s  a  p rog ress i ve  neurodegenera t i ve  d i so rde r  t ha t  a f fec t s  t he  mo to r  neurons  in  t he  
b ra in  and  sp ina l  cord .  I t  causes  musc le  weakness ,  t w i t ch ing ,  o r  c ramp ing  and 
Highlight and makes  i t  cha l leng ing  fo r  ind iv idua ls  t o  wa lk ,  speak ,  swa l l ow ,  and  b rea t he .  
I t  can  a lso  cause  loss  o f  musc le  con t ro l  and  eventua l  para l ys is  among  
Description i nd i v idua ls .  Bes ides  th is ,  i t  m ay  be  t rea ted  th rough  med ica l  approaches  to  enhance  t he  qua l i t y  o f  l i f e  o f  pa t ien t s ,  de lay  d isease p rogress ion ,  and  p rov ide  
suppor t i ve  ca re  to  add ress  t he  phys ica l ,  em ot iona l ,  and  func t iona l  cha l lenges  
posed  by  the  cond i t i on .
Request  fo r  a  PDF sample  o f  th is  repor t :  
ht tps : / / www. imarcgroup .com/amyot roph ic - l a t e ra l - sc le ros is - t r ea t men t -marke t / reque
s t samp le
Report Description
Global  Amyotrophic  Latera l  Sc leros is  Treatment  Market  Trends:
At  presen t ,  the  r is ing  awareness  about  ear ly  d iagnos is  and  t rea tment  o f  d iseases among ind iv idua ls  
represents  one o f  the ma jor  fac to rs  impel l ing  the g rowth  o f  the marke t .  In  add i t ion ,  the  increas ing  preva lence  
o f  ALS among the  masses wor ldwide is  cont r ibu t ing  to  the  g rowth o f  the  market .  Apar t  f rom th is ,  the growing  
demand for  e f fec t i ve  t rea tment  opt ions i s  pos i t i ve ly  in f luenc ing  the  market .  
Add i t iona l l y ,  the  increas ing  adopt ion  o f  ALS among the  ger ia t r i c  popu la t ion ,  as  they are  prone  to  
neurodegenerat i ve  d isorder ,  is  prope l l ing  the g rowth  o f  the market .  Bes ides  th is ,  the  r is ing  advancements  in  
medica l  techno logy and  innovat ions  in  drug deve lopment  are  suppor t ing  the g rowth  o f  the  marke t .
Looking forward ,  the  market  va lue  is  projected  to  reach US$ 1 ,112 .5  Mi l l ion by  2032,  expanding at  a  
CAGR of  4 .32% during 2024-2032.
View Report  TOC,  F igures  and Tables :  
ht tps: / /www. imarcgroup.com/amyotrophic- latera l -sc leros is - t reatment -market
Breakup by ALS Type:
• Sporadic ALS
• Famil ial  ALS  
Breakup by Drug Type:
• Marketed Drugs
• Emerging Drugs
Report 
Breakup by Diagnosis Type:
Segmentation
• Electromyogram
• MRI
• Blood and Urine Tests
• Spinal  Tap
• Muscle Biopsy
Breakup by Treatment:
• Medication
• Stem Cel l  Therapy
• Others
Breakup by Distribution Channel:
• Hospita l  Pharmacies
• Retai l  Pharmacies
• Others
Report 
Segmentation Breakup by Region:
• North America
• Asia-Pacifi c
• Europe
• Lat in America
• Middle East  and Afr ica
• AB Science
• Ascend Pharmaceuticals LLC
• BrainStorm Cell  Therapeutics Inc.
Competitive • Corestem Inc.
• Cytokinetics Inc.
Landscape 
• Eledon Pharmaceuticals Inc.
with Key • Ionis Pharmaceuticals Inc.
Players • ITF Pharma (Ita l farmaco S.p.A)
• Mitsubishi  Chemical Group Corpotion
• Revalesio Corporation
• Treeway B.V.
What was the size of the global amyotrophic lateral sclerosis 
treatment market in 2023?
What is the expected growth rate of the global amyotrophic 
lateral sclerosis treatment market during 2024-2032?
What are the key factors driving the global amyotrophic 
Key lateral sclerosis treatment market?
Questions What has been the impact of COVID-19 on the global 
amyotrophic lateral sclerosis treatment market?
Answered in 
What is the breakup of the global amyotrophic lateral 
the Report sclerosis treatment market based on the treatment?
What is the breakup of the global amyotrophic lateral 
sclerosis treatment market based on the distribution 
channel?
What are the key regions in the global amyotrophic lateral 
sclerosis treatment market?
Who are the key players/companies in the global 
amyotrophic lateral sclerosis treatment market?
1     P r e f a c e
2     S c o p e  a n d  M e t h o d o l o g y
    2 . 1     O b j e c t i v e s  o f  t h e  S t u d y
    2 . 2     S t a k e h o l d e r s
    2 . 3     D a t a  S o u r c e s
        2 . 3 . 1     P r i m a r y  S o u r c e s
        2 . 3 . 2     S e c o n d a r y  S o u r c e s
    2 . 4     M a r k e t  E s t i m a t i o n
        2 . 4 . 1     B o t t o m - U p  A p p r o a c h
Table of         2 . 4 . 2     T o p - D o w n  A p p r o a c h    2 . 5     F o r e c a s t i n g  M e t h o d o l o g y
3     E x e c u t i v e  S u m m a r y
4     I n t r o d u c t i o n
    4 . 1     O v e r v i e w
Contents     4 . 2     K e y  I n d u s t r y  T r e n d s5     G l o b a l  A m y o t r o p h i c  L a t e r a l  S c l e r o s i s  T r e a t m e n t  M a r k e t
    5 . 1     M a r k e t  O v e r v i e w
    5 . 2     M a r k e t  P e r f o r m a n c e
    5 . 3     I m p a c t  o f  C O V I D - 1 9
    5 . 4     M a r k e t  F o r e c a s t
6      M a r k e t  B r e a k u p  b y  A L S  T y p e
    6 . 1     S p o r a d i c  A L S
        6 . 1 . 1  M a r k e t  T r e n d s
        6 . 1 . 2  M a r k e t  F o r e c a s t
    6 . 2     F a m i l i a l  A L S
        6 . 2 . 1  M a r k e t  T r e n d s
        6 . 2 . 2  M a r k e t  F o r e c a s t
7    M a r k e t  B r e a k u p  b y  D r u g  T y p e
    7 . 1     M a r k e t e d  D r u g s
        7 . 1 . 1  M a r k e t  T r e n d s
        7 . 1 . 2  M a r k e t  F o r e c a s t
       
 7 . 2     E m e r g i n g  D r u g s
        7 . 2 . 1  M a r k e t  T r e n d s
        7 . 2 . 2  M a r k e t  F o r e c a s t
8    M a r k e t  B r e a k u p  b y  D i a g n o s i s  T y p e
    8 . 1     E l e c t r o m y o g r a m
        8 . 1 . 1  M a r k e t  T r e n d s
        8 . 1 . 2  M a r k e t  F o r e c a s t
    8 . 2     M R I
        8 . 2 . 1  M a r k e t  T r e n d s
        8 . 2 . 2  M a r k e t  F o r e c a s t
    8 . 3     B l o o d  a n d  U r i n e  T e s t s
Table of         8 . 3 . 1  M a r k e t  T r e n d s        8 . 3 . 2  M a r k e t  F o r e c a s t
    8 . 4     S p i n a l  T a p
        8 . 4 . 1  M a r k e t  T r e n d s
Contents         8 . 4 . 2  M a r k e t  F o r e c a s t
    8 . 5     M u s c l e  B i o p s y
        8 . 5 . 1  M a r k e t  T r e n d s
        8 . 5 . 2  M a r k e t  F o r e c a s t
9    M a r k e t  B r e a k u p  b y  T r e a t m e n t
    9 . 1     M e d i c a t i o n
        9 . 1 . 1  M a r k e t  T r e n d s
        9 . 1 . 2  M a r k e t  F o r e c a s t
    9 . 2     S t e m  C e l l  T h e r a p y
        9 . 2 . 1  M a r k e t  T r e n d s
        9 . 2 . 2  M a r k e t  F o r e c a s t
    9 . 3     O t h e r s  
        9 . 3 . 1  M a r k e t  T r e n d s
        9 . 3 . 2  M a r k e t  F o r e c a s t
F o r  m o r e  i n f o r m a t i o n ,  v i s i t :  
ht t ps : / /w ww. i ma rc gro up . c o m /a my o t ro ph i c - l a t e ra l - s c l e ros i s - t r
ea t m ent -m a rke t / t o c
Disclaimer
© 2023  IMARC Al l  R ights  Reserved 
Th is  Pub l i ca t ion  and  a l l  i t ’ s  con ten ts  un less  o therw ise  men t i oned  a re  copy r i gh ted  in  the  name o f  
I n t e rna t i ona l  Marke t  Ana lys i s  Research  and  Consu l t ing  ( IMARC) .  No  pa r t  o f  t h i s  pub l i ca t ion  may  be  
rep roduced ,  repackaged ,  red i s t r i bu ted  o r  res o ld  i n  who le  o r  i n  any  pa r t .  The  pub l i ca t ion  may  a l so  
no t  be  used  i n  any  f o rm o r  by  and means  g raph i c  e lec t ron ic  o r  mechan ic a l ,  i nc lud ing  pho tocopy ing ,  
reco rd ing ,  t ap ing  o r  by  i n fo rmat i on  s to rage  o r  re t r ieva l ,  o r  by  any  o the r  f o rm,  w i t hou t  the  exp ress  
c ons en t  o f  I n t e rna t iona l  Marke t  Ana lys i s  Research  and  Consu l t i ng  ( IMARC) .
Disc la imer :  Al l  con ten ts  and  da ta  o f  t h i s  pub l i c a t i on ,  i nc lud ing  fo recas t s ,  da ta  ana lys i s  and  op in ion  
have  been  based  on  in f o rmat ion  and  sources  be l ieved  to  be  accu ra te  and  re l iab le  a t  t he  t ime  o f  
pub l i sh ing .  In t e rna t i ona l  Ma rke t  Ana l ys is  Research  and  Consu l t ing  makes  no  rep resen ta t ion  o f  
war ran t y  o f  any  k ind  as  to  t he  acc u racy  o r  comp le teness  o f  any  I n fo rmat i on  p rov ided .  IMARC 
accep ts  no  l i ab i l i t y  wha tsoever  f o r  any  los s  o r  damage  resu l t i ng  f rom op in ion ,  e r ro rs  o r  
i naccu rac ies  i f  any  f ound  th is  pub l i ca t ion .
IMARC,  IMARC Group  and  G loba l  Therapy  I ns igh t  Ser i es  a re  reg is t e red  t rademarks  o f  I n te rna t iona l  
Marke t  Ana lys i s  Research  and  Consu l t ing .  A l l  o the r  t rademarks  used  i n  th i s  pub l i ca t i on  a re  
reg i s te red  t rademarks  o f  t he i r  r espec t i ve  compan ies .
Contact Us
Visit us at :
https://www.imarcgroup.com
TELEPHONE: +1-631-791-1145 
E-MAIL: [email protected]